Evidence map›Paper›PMID 31009148›Full record

ArticleCellular microbiology2019

Cholix toxin, an eukaryotic elongation factor 2 ADP-ribosyltransferase, interacts with Prohibitins and induces apoptosis with mitochondrial dysfunction in human hepatocytes.

Kinnosuke Yahiro, Kohei Ogura, Yasuhiro Terasaki, Mamoru Satoh, Satoru Miyagi, Mika Terasaki, Eiki Yamasaki, Joel Moss

Open access · greenAbstract read
In one paragraph

Article in Cellular microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. NAD metabolism in aging and cancer.Experimental biology and medicine (Maywood, N.J.) · 2020
    Article
  9. Virulence Regulation and Innate Host Response in the Pathogenicity ofFrontiers in cellular and infection microbiology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 2 countries.

Kinnosuke YahiroDepartment of Molecular Infectiology, Graduate School of Medicine, Chiba University, Chiba, Japan.ORCID 0000-0002-9813-0780
Kohei OguraAdvanced Health Care Science Research Unit, Institute for Frontier Science Initiative, Kanazawa University, Kanazawa, Japan.
Yasuhiro TerasakiDepartment of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan.ORCID 0000-0003-4495-7982
Mamoru SatohDivision of Clinical Mass Spectrometry, Chiba University Hospital, Chiba, Japan.
Satoru MiyagiDepartment of Life Science, Faculty of Medicine, Shimane University, Izumo, Japan.
Mika TerasakiDepartment of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan.
Eiki YamasakiDiagnostic Center for Animal Health and Food Safety, Obihiro University of Agriculture and Veterinary Medicine, Hokkaido, Japan.
Joel MossPulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Nippon Medical School Hospital · JPChiba University · JPChiba University Hospital · JPKanazawa University · JPNational Institutes of Health · USObihiro University of Agriculture and Veterinary Medicine · JPShimane University · JP

Funding

ADP-ribosylation CyclesZIAHL000659 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI MOSS, JOEL · 2009 to 2025
$29.8M
ADP-RIBOSYLATION CYCLESZ01HL000659 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI MOSS, JOEL · 1993 to 2008
$2.1M
Intramural NIH HHS Z01 HL000659
6 · The paper itself

Abstract

Vibrio cholerae produced-Cholix toxin (Cholix) is a cytotoxin that ADP-ribosylates eukaryotic elongation factor 2, inhibiting protein synthesis, and inducing apoptosis. Here, we identified prohibitin (PHB) 1 and 2 as novel Cholix-interacting membrane proteins in immortalised human hepatocytes and HepG2 cells by Cholix immunoprecipitation assays. The expression level of PHB1 was decreased by Cholix after a 12hr incubation. Cholix-induced poly (ADP-ribose) polymerase (PARP) cleavage was significantly enhanced in PHB (PHB1 or PHB2) knockdown cells. In contrast, transiently overexpressed PHB in hepatocytes attenuated Cholix-induced Bax/Bak conformational changes and PARP cleavage. In addition, Cholix-induced reactive oxygen species production and accumulation of fragmented mitochondria were enhanced in PHB-knockdown cells. Furthermore, Cholix induced activation of Rho-associated coiled coil-containing protein kinase 1 (ROCK1), which was enhanced in PHB-knockdown cells, followed by actin filament depolymerisation and accumulation of tubulin in the blebbing cells. Inhibition of ROCK1 by siRNA or its inhibitor suppressed Cholix-induced PARP cleavage and reactive oxygen species generation. Our findings identify PHB as a new protein that interacts with Cholix and is involved in Cholix-induced mitochondrial dysfunction and cytoskeletal rearrangement by ROCK1 activation during apoptosis.

Indexed as

Actin CytoskeletonADP-RibosylationADP-Ribosylation FactorsAmino Acid SequenceApoptosisBacterial Toxinsbcl-2-Associated X Proteinbcl-2 Homologous Antagonist-Killer ProteinCell Line, TransformedEukaryotic Initiation Factor-2Gene Expression RegulationHepatocytesHep G2 CellsHost-Pathogen InteractionsHumansMitochondriaADP-Ribosylation FactorsBacterial ToxinsBAK1 protein, humanBAX protein, humanbcl-2-Associated X Proteinbcl-2 Homologous Antagonist-Killer Proteincholix toxin, Vibrio choleraeEukaryotic Initiation Factor-2PHB2 protein, humanPHB protein, humanProhibitinsProtein IsoformsReactive Oxygen SpeciesRepressor Proteinsrho-Associated KinasesRNA, Small InterferingROCK1 protein, humanTubulincell deathCholixmitochondriaprohibitinROS generation

Identifiers

PMID31009148
PMCPMC9986844
OpenAlexW2941401106

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.